Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers

June 13, 2016

SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was conducted of 105 patients treated with dalbavancin at 16 nationwide infectious disease physician office infusion centers (POICs) from July 2014 to March 2015. Treatment characteristics, microbiology, safety, efficacy, and disease recurrences were evaluated. 

Dalbavancin was used in treating a variety of infections including cellulitis (45%), abscess (28%), osteomyelitis (12%), diabetic foot infections (11%), and prosthetic device infections (4%). The most frequent microorganism identified in this patient population was Staphylococcus aureus.  MRSA was the pathogen identified in 48% of patients and MSSA in 17%. Dalbavancin was used following other intravenous antibiotics in 53% of patients. Overall clinical success was reported in 84% of patients, including 52% cured and 32% improved.  Highest success rates were found in cellulitis with 87%.  Failure to respond to therapy was largely a result of adverse events (10/15 patients).  Overall adverse events occurred in 30 patients, with diarrhea most prevalent (9.5%), followed by hypersensitivity reactions (8.6%), all with resolution except one lost to follow-up.  Sixty-day recurrence rates in 82 evaluable patients were low at 9%.    

The results of this study provided evidence that dalbavancin can be a safe and effective treatment option in a physician office infusion center setting. To learn more, click here.

This study was presented at IDWeek 2015™. For a printed copy of this research poster study, please call 1.866.654.2451 or email marketing@healix.net.

ABOUT HEALIX, INC.                                                                                                                        

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2015™                                                                                                                   

IDWeek 2015™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2015 took place October 7-11 at the San Diego Convention Center in San Diego, California. For more information, visit www.idweek.org.